

The Valens Company

08:13 12 Dec 2019

Valens widens exclusive licence pact to bring cannabis-infusion technology to new markets

Valens GroWorks Corp (CVE:VGW) (OTCMKTS:VGWCF) said Thursday that it has struck an amended manufacturing and sales licence agreement with S?RSE Technology Corporation, which granted it an exclusive licence for Canada, Europe, Australia and Mexico to use the proprietary S?RSE emulsion technology to produce, sell and distribute cannabis-infused products.

In a statement, the British Columbia-based vertically integrated provider of extraction products and services said that with the "expanded agreement" in place, the company has extended the opportunity for its existing customers to key international markets.

"This agreement shows Valens' commitment to invest and broaden its IP portfolio and enable its customers to bring differentiated, next-generation products to market," said Jeff Fallows, president of Valens.

READ: Valens GroWorks Corp earns Buy recommendation from Power Growth Investor

"As we move into "Cannabis 2.0" in Canada, we believe the products that offer consistent, high quality and predictable user experiences, like those we are able to create with S?RSE, will capture the lion's share of attention and be the hallmark for brand development in a strict regulatory environment," he added.

S?RSE emulsion technology

S?RSE Technology is a water-soluble emulsion technology for infusing products with CBD, THC, and terpenes. It transforms cannabis oil into water-soluble forms for use in beverages, edibles, and other consumer products without the overpowering cannabis taste, colour or smell. The technology allows cannabis-infused products to remain potent when heated, chilled or frozen and provides a number of other key advantages like a faster onset time compared to other infused beverages and edibles, a significant reduction of offset time, an ability to use lower doses of CBD, and increased consistency and stability. Some product formulations can achieve more than one year of shelf stability with no separation.

"We are proud to expand our partnership with Valens and leverage their near-term access to various global markets," said S?RSE Technology Corp CEO Howard Lee.

Lee said that over the last year, a team of more than 40-plus professionals has continued to "actively focus" on creating and developing innovative, desirable products and formats of consumption for cannabis consumers.

"As emulsion technology becomes more popular through new delivery methods such as ingestion, transdermal, topical and more, it is imperative that quality and safety in consumption leads all innovation in this sector," said Lee.

"This is a shared value and mandate that our teams at S?RSE and Valens both prioritize. We look forward to continuing this working relationship with Valens and introducing our award-winning emulsion technology to the global markets," he

Price: 3.93

Market Cap: \$493.23 m

1 Year Share Price Graph



Share Information

Code: VLNS

Listing: TSX-V

52 week	High	Low
	4.1	2.95

Sector: Cannabis

Website: thevalenscompany.com

Company Synopsis:

The Valens Company is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO₂, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development.

action@proactiveinvestors.com

added.

Geographic expansion

The agreement grants Valens an exclusive licence to use the technology in Canada, Europe, Australia and Mexico (except in respect of medical applications requiring clinical trials) during the initial five-year term, subject to certain performance milestones.

This increases the addressable market from 37 million in the current Canada only agreement to 700 million people in the new agreement, said the company.

Most significantly, the agreement provides a framework for Valens to obtain rights to establish non-exclusive agreements to sell cannabis-infused products using the technology in the US market and other markets, globally.

Bolstering Cannabis 2.0 platform

The agreement adds to the company's leading white label product offerings across numerous "Cannabis 2.0" categories such as beverages, edibles, and transdermal products, enabling Valens to better serve its partners.

"We have seen incredible interest from our current and potential clients regarding the S?RSE emulsion technology and we are thrilled to finalize the expanded licence agreement with S?RSE," said Valens CEO Tyler Robson.

"We expect the expanded exclusive territory will provide our clients with improved visibility and greater opportunity as they look to build global businesses around cannabis-infused products over the long term," he added.

Future White Label services

The agreement enables Valens to produce and sell S?RSE's portfolio of branded products in Canada and the other exclusive markets. These branded products include Happy Apple, a cannabis-infused sparkling cider and Major, a cannabis-infused fruit drink, both top-selling cannabis beverages in the State of Washington, Pearl20, a cannabis-infused food and beverage mixer, and the Utopia line of cannabis-infused sparkling water.

For the deal to go through Valens will fork over US\$10 million, consisting of US\$6 million in cash and US\$4 million in company shares. There is an initial five-year exclusive term, with a two-year renewal of the exclusivity, subject to certain performance milestones linked to operational and financial achievements.

As part of the agreement, Valens will transfer to S?RSE royalty payments calculated as a percentage of sales. The royalty payments will be subject to an annual minimum of \$2 million over the five-year term. The pact also provides for a continuation of the deal on a non-exclusive basis after the two-year renewal, subject to annual minimum royalty payments.

Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at its purpose-built facility in Kelowna, British Columbia.

— Adds monetary details, Valens CEO quotes —

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of The Valens Company named herein, including the promotion by the Company of The Valens Company in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).